11:53 ET - ESG investors may choose to avoid companies for their alleged roles tied to the opioid crisis in the US. This week's trial against Johnson & Johnson, which Purdue Pharma and Teva Pharmaceuticals agreed to settle, is one of 2,000 lawsuits lined up against drug makers, retailers and distributors of opioids. The claims involve aggressive and irresponsible marketing, as well as the spreading of misinformation regarding their drugs. These social factors may make these companies look less attractive to ESG investors. For activist investors, these suits could provide an opportunity to push for company-level changes aligned with their investment views. (christian.brunnstrom@dowjones.com)

(END) Dow Jones Newswires

May 28, 2019 12:08 ET (16:08 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Johnson and Johnson
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Johnson and Johnson